Literature DB >> 24157357

Protein engineering strategies for the development of viral vaccines and immunotherapeutics.

Jayne F Koellhoffer1, Chelsea D Higgins1, Jonathan R Lai2.   

Abstract

Vaccines that elicit a protective broadly neutralizing antibody (bNAb) response and monoclonal antibody therapies are critical for the treatment and prevention of viral infections. However, isolation of protective neutralizing antibodies has been challenging for some viruses, notably those with high antigenic diversity or those that do not elicit a bNAb response in the course of natural infection. Here, we discuss recent work that employs protein engineering strategies to design immunogens that elicit bNAbs or engineer novel bNAbs. We highlight the use of rational, computational, and combinatorial strategies and assess the potential of these approaches for the development of new vaccines and immunotherapeutics.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody engineering; Antiviral immunotherapy; Immunogen design

Mesh:

Substances:

Year:  2013        PMID: 24157357      PMCID: PMC3947166          DOI: 10.1016/j.febslet.2013.10.014

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  91 in total

Review 1.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

2.  Monoclonal antibodies in cancer therapy: 25 years of progress.

Authors:  Robert K Oldham; Robert O Dillman
Journal:  J Clin Oncol       Date:  2008-04-10       Impact factor: 44.544

3.  An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.

Authors:  Adi Moseri; Subramanyam Tantry; Yael Sagi; Boris Arshava; Fred Naider; Jacob Anglister
Journal:  Virology       Date:  2010-03-26       Impact factor: 3.616

4.  Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change.

Authors:  Matthew Brecher; Kathryn L Schornberg; Sue E Delos; Marnie L Fusco; Erica Ollmann Saphire; Judith M White
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

5.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

6.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

7.  Rapid structural characterization of human antibody-antigen complexes through experimentally validated computational docking.

Authors:  Luca Simonelli; Martina Beltramello; Zinaida Yudina; Annalisa Macagno; Luigi Calzolai; Luca Varani
Journal:  J Mol Biol       Date:  2010-01-04       Impact factor: 5.469

Review 8.  Antiviral antibody responses: the two extremes of a wide spectrum.

Authors:  Lars Hangartner; Rolf M Zinkernagel; Hans Hengartner
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

9.  Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Authors:  Matthew S Miller; Thomas J Gardner; Florian Krammer; Lauren C Aguado; Domenico Tortorella; Christopher F Basler; Peter Palese
Journal:  Sci Transl Med       Date:  2013-08-14       Impact factor: 17.956

10.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

View more
  6 in total

1.  Detection of Regional Variation in Selection Intensity within Protein-Coding Genes Using DNA Sequence Polymorphism and Divergence.

Authors:  Zi-Ming Zhao; Michael C Campbell; Ning Li; Daniel S W Lee; Zhang Zhang; Jeffrey P Townsend
Journal:  Mol Biol Evol       Date:  2017-11-01       Impact factor: 16.240

2.  Glycosylation of the HIV-1 Env V1V2 loop to form a native-like structure may not be essential with a nanoparticle vaccine.

Authors:  Christopher P Karch; Gary R Matyas; Peter Burkhard; Zoltan Beck
Journal:  Future Virol       Date:  2019-01-10       Impact factor: 1.831

Review 3.  Peptide-Based Vaccines: Current Progress and Future Challenges.

Authors:  Ryan J Malonis; Jonathan R Lai; Olivia Vergnolle
Journal:  Chem Rev       Date:  2019-12-05       Impact factor: 60.622

Review 4.  The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing.

Authors:  Parichehr Hassanzadeh
Journal:  Life Sci       Date:  2021-03-04       Impact factor: 6.780

Review 5.  COVID-19: A systematic review and update on prevention, diagnosis, and treatment.

Authors:  Hooman Aghamirza Moghim Aliabadi; Reza Eivazzadeh-Keihan; Arezoo Beig Parikhani; Sara Fattahi Mehraban; Ali Maleki; Sepideh Fereshteh; Masoume Bazaz; Ashkan Zolriasatein; Bahareh Bozorgnia; Saman Rahmati; Fatemeh Saberi; Zeinab Yousefi Najafabadi; Shadi Damough; Sara Mohseni; Hamid Salehzadeh; Vahid Khakyzadeh; Hamid Madanchi; Gholam Ali Kardar; Payam Zarrintaj; Mohammad Reza Saeb; Masoud Mozafari
Journal:  MedComm (2020)       Date:  2022-02-17

Review 6.  Antibody engineering for increased potency, breadth and half-life.

Authors:  Stuart A Sievers; Louise Scharf; Anthony P West; Pamela J Bjorkman
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.